Cargando…

Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients

Background: The cytochrome P450 drug metabolizing enzymes CYP2D6 and CYP2C19 are the major targets for pharmacogenomics (PGx) testing and determining for drug response. Clinical dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB. The aim of this regis...

Descripción completa

Detalles Bibliográficos
Autores principales: Westergaard, Niels, Søgaard Nielsen, Regitze, Jørgensen, Steffen, Vermehren, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151550/
https://www.ncbi.nlm.nih.gov/pubmed/31963319
http://dx.doi.org/10.3390/jpm10010003
_version_ 1783521276460007424
author Westergaard, Niels
Søgaard Nielsen, Regitze
Jørgensen, Steffen
Vermehren, Charlotte
author_facet Westergaard, Niels
Søgaard Nielsen, Regitze
Jørgensen, Steffen
Vermehren, Charlotte
author_sort Westergaard, Niels
collection PubMed
description Background: The cytochrome P450 drug metabolizing enzymes CYP2D6 and CYP2C19 are the major targets for pharmacogenomics (PGx) testing and determining for drug response. Clinical dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB. The aim of this register study was to map the use of drugs in Denmark for drugs having actionable dosing guidelines (AG) i.e., dosing recommendations different from standard dosing for CYP2D6 or CYP2C19 DGI in terms of consumption. Methods: The Danish Register of Medicinal Product Statistics was the source to retrieve consumption in Defined Daily Dose (DDD) i.e., the assumed average maintenance dose per day for a drug used for its main indication in adults and number of users (2017 data). Clinical dosing guidelines were available from the PharmGKB website. Results: Forty-nine drugs have guidelines corresponding to 14.5% of total sales in DDD. Twenty-eight drugs have AG corresponding to 375.2 million DDD. Pantoprazole, lansoprazole, omeprazole, clopidogrel, and metoprolol constituted fifty-eight percent of the consumption in DDD of drugs having AG. The consumption of antidepressant drugs, opioids, and antipsychotic drugs were 157.0 million DDD; with 441,850 users, 48.9 million DDD; with 427,765 users, and 23.7 million DDD; with 128,935 users, respectively. Age distributions of consumption of drugs and drug combinations, e.g., for sertraline redeemed either alone or in combination with metoprolol and tramadol, are presented. Conclusion: This exploratory register study clearly showed that a large fraction of the Danish population, especially the elderly, are exposed to drugs or drug combinations for which there exist AG related to PGx of CYP2D6 or CYP2C19.
format Online
Article
Text
id pubmed-7151550
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71515502020-04-20 Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients Westergaard, Niels Søgaard Nielsen, Regitze Jørgensen, Steffen Vermehren, Charlotte J Pers Med Article Background: The cytochrome P450 drug metabolizing enzymes CYP2D6 and CYP2C19 are the major targets for pharmacogenomics (PGx) testing and determining for drug response. Clinical dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB. The aim of this register study was to map the use of drugs in Denmark for drugs having actionable dosing guidelines (AG) i.e., dosing recommendations different from standard dosing for CYP2D6 or CYP2C19 DGI in terms of consumption. Methods: The Danish Register of Medicinal Product Statistics was the source to retrieve consumption in Defined Daily Dose (DDD) i.e., the assumed average maintenance dose per day for a drug used for its main indication in adults and number of users (2017 data). Clinical dosing guidelines were available from the PharmGKB website. Results: Forty-nine drugs have guidelines corresponding to 14.5% of total sales in DDD. Twenty-eight drugs have AG corresponding to 375.2 million DDD. Pantoprazole, lansoprazole, omeprazole, clopidogrel, and metoprolol constituted fifty-eight percent of the consumption in DDD of drugs having AG. The consumption of antidepressant drugs, opioids, and antipsychotic drugs were 157.0 million DDD; with 441,850 users, 48.9 million DDD; with 427,765 users, and 23.7 million DDD; with 128,935 users, respectively. Age distributions of consumption of drugs and drug combinations, e.g., for sertraline redeemed either alone or in combination with metoprolol and tramadol, are presented. Conclusion: This exploratory register study clearly showed that a large fraction of the Danish population, especially the elderly, are exposed to drugs or drug combinations for which there exist AG related to PGx of CYP2D6 or CYP2C19. MDPI 2020-01-16 /pmc/articles/PMC7151550/ /pubmed/31963319 http://dx.doi.org/10.3390/jpm10010003 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Westergaard, Niels
Søgaard Nielsen, Regitze
Jørgensen, Steffen
Vermehren, Charlotte
Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
title Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
title_full Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
title_fullStr Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
title_full_unstemmed Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
title_short Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
title_sort drug use in denmark for drugs having pharmacogenomics (pgx) based dosing guidelines from cpic or dpwg for cyp2d6 and cyp2c19 drug–gene pairs: perspectives for introducing pgx test to polypharmacy patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151550/
https://www.ncbi.nlm.nih.gov/pubmed/31963319
http://dx.doi.org/10.3390/jpm10010003
work_keys_str_mv AT westergaardniels druguseindenmarkfordrugshavingpharmacogenomicspgxbaseddosingguidelinesfromcpicordpwgforcyp2d6andcyp2c19druggenepairsperspectivesforintroducingpgxtesttopolypharmacypatients
AT søgaardnielsenregitze druguseindenmarkfordrugshavingpharmacogenomicspgxbaseddosingguidelinesfromcpicordpwgforcyp2d6andcyp2c19druggenepairsperspectivesforintroducingpgxtesttopolypharmacypatients
AT jørgensensteffen druguseindenmarkfordrugshavingpharmacogenomicspgxbaseddosingguidelinesfromcpicordpwgforcyp2d6andcyp2c19druggenepairsperspectivesforintroducingpgxtesttopolypharmacypatients
AT vermehrencharlotte druguseindenmarkfordrugshavingpharmacogenomicspgxbaseddosingguidelinesfromcpicordpwgforcyp2d6andcyp2c19druggenepairsperspectivesforintroducingpgxtesttopolypharmacypatients